Head of US Commercial Operations at Dyno Therapeutics

Waltham, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, Neuromuscular DiseaseIndustries

Requirements

Candidates should possess a BA/BS degree, with an advanced degree (MBA, PhD, PharmD) being preferred. A minimum of 10 years of progressive experience in biopharmaceutical commercial operations is required, including at least 5 years in a leadership role. Proven success in leading product launches and driving revenue growth within rare disease or specialty pharmaceutical markets is essential, along with a strong reputation for excellent cross-functional collaboration.

Responsibilities

The Head of US Commercial Operations will serve as a key member of the US Commercial Leadership Team, developing and executing commercial operations strategy and operating plans for product launches in Duchenne Muscular Dystrophy and myotonic dystrophy Type I. This role involves building and managing critical commercial infrastructure, including sales operations, analytics, forecasting, market access operations, and commercial systems. Responsibilities include leading commercial planning processes, building and overseeing a sales operations team, establishing data governance, partnering cross-functionally, designing KPIs and reporting frameworks, leading field force enablement, supporting compliant policies, and managing operational budgets, contracts, and vendor relationships.

Skills

Sales Operations

Analytics

Forecasting

Market Access

Commercial Systems

Incentive Compensation

Market Research

Data Management

CRM Systems

Field Effectiveness

Commercial Training

Strategic Leadership

Cross-functional Collaboration

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Watertown, MassachusettsHeadquarters

2018Year Founded

$106MTotal Funding

SERIES_ACompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.

Manufacturing bottlenecks could hinder scaling of Dyno's operations.

Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.

Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.

Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.

Collaboration with NVIDIA enhances biological sequence design for gene therapies.

Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI

Try Jobo Free